Tonghua Dongbao Pharmaceutical Co., Ltd. researches and develops, manufactures, and sells pharmaceutical for the treatment of diabetes, endocrine, and cardiovascular and cerebrovascular diseases products in China. It offers human insulin API and injections; insulin glargine API and injections; insulin aspart API and injections; liraglutide injections; zhennaoning capsules; and diabetes-related medical devices. The company also provides insulin pen and needle injection system, blood sugar monitoring system, and online and offline patient management system.
